AR043694A1 - Derivados ciclicos como moduladores de la actividad del receptor de quimiocina - Google Patents
Derivados ciclicos como moduladores de la actividad del receptor de quimiocinaInfo
- Publication number
- AR043694A1 AR043694A1 ARP040100419A ARP040100419A AR043694A1 AR 043694 A1 AR043694 A1 AR 043694A1 AR P040100419 A ARP040100419 A AR P040100419A AR P040100419 A ARP040100419 A AR P040100419A AR 043694 A1 AR043694 A1 AR 043694A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- crr
- alkyl
- alkynyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto cíclico de la fórmula (1) o un estereoisómero o una sal farmacéuticamente aceptable de los mismos, en donde el anillo B es un grupo cicloalquilo de 3 hasta 8 átomos de carbono en donde el grupo cicloalquilo está saturado o parcialmente insaturado; o un heterociclo de 3 hasta 7 átomos en donde el heterociclo está saturado o parcialmente insaturado, el heterociclo contiene un heteroátomo seleccionado de -O-, -S-, -S(=O)-, -S(=O)2-, y -N(R4)-, el heterociclo contiene opcionalmente un -C(O)-; el anillo B está substituido con 0-2 R5; X se selecciona de O ó S; Z se selecciona de un enlace, -C(O)-, y -C(O)NR8-, NR8C(S)-, NR8C(O)NH-, NR8C(S)NH-, NR8SO2-, NR8SO2NH-, -C(O)NR8-, -OC(O)NR8-, -NR8C(O)O-, -(CR15R15)-, -CR14=CR14-, -CR15R15C(O)-, -C(O)R15R15-, -CR15R15C(=N-OR16)-, -O-CR14R14-, -CR14R14-O-, -O-, _NR9-, -NR9-CR14R14-, -CR14R14-NR9-, -S(O)p-, -S(O)p-CR14R14-, -CR14R14-S(O)p-, y -S(O)p-NR9; en donde ni Z ni R13 se conectan al átomo de carbono etiquetado (b); el enlace (a) es un enlace sencillo o doble; alternativamente, cuando n es igual a 2, dos átomos etiquetados (b) pueden unirse a través de un enlace doble; E se selecciona de -S(O)pCHRe-, -CHReNRe-, -C(O)-NRe-, -NReC(O)NRe-, -SO2-NRe-, y -NReSO2NRe ;Re se selecciona independientemente de H y alquilo C1-3; R1 se selecciona de un grupo arilo C6-10 substituido con 0-5 R6 y un sistema heteroarilo de 5-10 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-3 R6 ;R2 se selecciona de un grupo C6-10 arilo substituido con 0-5 R7 y un sistema heteroarilo de 5-10 miembros que contiene 1-4 heteroátomos seleccionados de N, O, y S, substituido con 0-3 R7; R4 se selecciona de H, alquilo C1-6, alquenilo C3-8, alquinilo C3-8, (CRR)tOH, (CRR)tSH, (CRR)tOR4d, (CHR)tSR4d, (CRR)tNR4aR4a, (CRR)qC(O)OH, (CRR)rC(O)R4b, (CRR)rC(O)NR4aR4a, (CRR)tOC(O)NR4aR4a, (CRR)tNR4aC(O)OR4d, (CRR)tNR4aC(O)R4b, (CRR)rC(O)OR4d, (CRR)tOC(O)R4b, (CRR)rS(O)pR4b, (CRR)rS(O)2NR4aR4a, (CRR)tNR4aS(O)2R4b, haloalquilo C1-6, un residuo carbocíclico (CRR)r-C3-10 substituido con 0-3 R4e, y un sistema heterocíclico (CHR)r- de 4-10 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-2 R4e ; R4a, cada vez que se presenta, se selecciona independientemente de H, metilo substituido con 0-1R4C, alquilo C2-6 substituido con 0-3 R4e, alquenilo C3-8 substituido con 0-3 R4e, alquinilo C3-8 substituido con 0-3 R4e, un residuo carbocíclico(CH2)r- C3-10 substituido con 0-4 R4e, y un sistema heterocíclico (CHR)r- de 4-10 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-2 R4e ; R4b, cada vez que se presenta, se selecciona de H, alquilo C1-6 substituido con 0-3R4e, alquenilo C3-8 substituido con 0-3 R4e, alquinilo C3-8 substituido con 0-3 R4e, un residuo carbocíclico (CH2)r- C3-6 substituido con 0-2 R4e, y un sistema heterocíclico (CHR)r- de 4-10 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-2 R4e; R4c se selecciona independientemente de -C(O)R4b, -C(O)OR4d, -C(O)NR4fR4f, y (CH2)rfenilo; R4d, cada vez que se presenta, se selecciona de metilo, CF3, alquilo C2-6 substituido con 0-3R4e, alquenilo C3-8 substituido con 0-3R4e, alquinilo C3-8 substituido con 0-3 R4e, y un residuo carbocíclico C3-10 substituido con 0-3 R4e ; R4e, cada vez que se presenta, se selecciona de alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo (CH2)rC3-6, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOalquilo C1-5, OH, SH, (CH2)rSalquilo C1-5, (CH2)rNR4fR4f, -C(O)R4i, -C(O)OR4j, -C(O)NR4hR4h, -OC(O)NR4hR4h, -NR4hC(O)NR4hR4h, -NR4hC(O)OR4h, y (CH2)rfenilo; R4f cada vez que se presenta, se selecciona de H, alquilo C1-6, cicloalquilo C3-6 y fenilo; R4h cada vez que se presenta, se selecciona independientemente de H, alquilo C1-6, alquenilo C3-8, alquinilo C3-8 y un carbociclo (CH2)r C3-10; R4i cada vez que se presenta, se selecciona de H, alquilo C1-6, alquenilo C3-8, alquinilo C3-8 y un carbociclo (CH2)r C3-10; R4j cada vez que se presenta, se selecciona de CF3, alquilo C1-6, alquenilo C3-8, alquinilo C3-8 y un residuo carbocíclico C3-10; R5, cada vez que se presenta, se selecciona independientemente H, =O, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, (CRR)rOH, (CRR)rSH, (CRR)rOR5d, (CRR)rSR5d, (CRR)rNR5aR5a, (CRR)rN(->O)R5aR5a, N3, (CRR)rC(O)OH, (CRR)rC(O)R5b, (CRR)rC(O)NR5aR5a, (CRR)rNR5aC(O)R5b, (CRR)rOC(O)NR5aR5a, (CRR)rNR5aC(O)OR5d, (CRR)rNR5aC(O)NR5aR5a, (CRR)rNR5aC(O)H, (CRR)rC(O)OR5d, (CRR)rOC(O)R5b, (CRR)rS(O)pR5b, (CRR)rS(O)2NR5aR5a, (CRR)rNR5aS(O)2R5b, (CRR)rNR5aS(O)2NR5aR5a, haloalquilo C1-6, un residuo carbocíclico (CRR)r- C3-10 substituido con 0-3 R5c, y un sistema heterocíclico (CRR)r de 5-10 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-2 R5c; R5a, cada vez que se presenta, se selecciona independientemente de H, metilo substituido con 0-1 R5g, alquilo C2-6 substituido con 0-2 R5e, alquenilo C3-8 substituido con 0-2 R5e, alquinilo C3-8 substituido con 0-2 R5e, un residuo carbocíclico (CH2)r- C3-10 substituido con 0-5 R5e, un sistema heterocíclico (CH2)r de 5-10 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-3R5e; R5b cada vez que se presenta, se selecciona de alquilo C1-6 substituido con 0-3 R5e, alquenilo C3-8 substituido con 0-2 R5e, alquinilo C3-8 substituido con 0-2 R5e, un residuo carbocíclico(CH2)r- substituido con 0-2 R5e y un sistema heterocíclico(CH2)r de 5-6 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-3 R5e; R5c, cada vez que se presenta, se selecciona de alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo(CH2)r C3-6, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR5fR5f, (CH2)rOH, (CH2)rOalquilo C1-4, (CH2)rSalquilo C1-4, (CH2)rC(O)OH, (CH2)rC(O)R5b, (CH2)rC(O)NR5fR5f, (CH2)rOC(O)NR5fR5f, (CH2)rNR5fC(O)R5b, (CH2)rC(O)Oalquilo C1-4, (CH2)rNR5fC(O)Oalquilo C1-4, (CH2)rOC(O)R5b, (CH2)C(=NR5f)R5fR5f, (CH2)rS(O)pR5b, (CH2)rNHC(=NR5f)NR5fR5f, (CH2)rS(O)2NR5fR5f, (CH2)NR5fS(O)2R5b y (CH2)rfenilo substituido con 0-3 R5e; R5d cada vez que se presenta, se selecciona de metilo, CF3, alquilo C2-6 substituido con 0-2 R5e, alquenilo C3-8 substituido con 0-2 R5e, alquinilo C3-8 substituido con 0-2 R5e, un residuo carbocíclico C3-10 substituido con 0-3 R5e; R5e cada vez que se presenta, se selecciona de alquilo C1-6, alquenilo C2-8, alquinilo C2-8,cicloalquilo C3-6, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOalquilo C1-5, OH, SH, (CH2)rSalquilo C1-5, (CH2)rNR5fR5f, y (CH2)rfenilo; R5f, cada vez que se presenta, se selecciona de H, alquilo, y cicloalquilo ; R5g se selecciona independientemente de -C(O)R5b, -C(O)OR5d, - C(O)NR5fR5f, CN, y (CH2)rfenilo ; R, cada vez que se presenta, se selecciona de H, alquilo C1-6 substituido con R5e, alquenilo C2-8, alquinilo C2-8, cicloalquilo(CH2)r C3-6, y (CH2)rfenilo substituido con R5e ;R6, cada vez que se presenta, se selecciona de alquilo C1-8, alquenilo, alquinilo, cicloalquilo(CH2)r C3-6, Cl, Br, I, F, NO2, CN, (CR'R')rNR6aR6a, (CR'R')rOH, (CR'R')rO(CR'R')rR6d, (CR'R')rSH, (CR'R')rC(O)H, (CR'R')rS(CR'R')rR6d, (CR'R')rSC(O)(CR'R')rR6b, (CR'R')rC(O)OH, (CR'R')rC(O)(CR'R')rR6b, (CR'R')rNR6aR6a, (CR'R')rC(O)NR6aR6a, (CR'R')rNR6fC(O)(CR'R')rR6b, (CR'R')rC(O)O(CR'R')rR6d, (CR'R')rOC(O)(CR'R')rR6b, (CR'R')rOC(O)NR6a(CR'R')rR6d, (CR'R')rNR6aC(O)NR6a(CR'R')rR6d, (CR'R')rNR6aC(S)NR6a(CR'R')rR6d, (CR'R')rNR6fC(O)O(CR'R')rR6b, (CR'R')rC(=NR6f)NR6aR6a, (CR'R')rNHC(=NR6f)NR6fR6f, (CR'R')rS(O)p(CR'R')rR6b, (CR'R')rS(O)2NR6aR6a, (CR'R')rNR6fS(O)2NR6aR6a, (CR'R')rNR6fS(O)2(CR'R')rR6b, haloalquilo, alquenilo substituido con 0-3 R', alquinilo substituido con 0-3 R', (CR'R')rfenilo substituido con 0-3 R6e, y un sistema heterocíclico(CH2)r de 5-6 miembros que contiene 1-2 heteroátomos seleccionado de N, O, y S, substituido con 0-2 R6e ; alternativamente, dos R6 en los átomos adyacentes en R1 pueden unirse para formar un acetal cíclico; R6a, cada vez que se presenta, se selecciona de H, metilo substituido con 0-1 R6g,alquilo substituido con 0-2 R6e, alquenilo substituido con 0-2 R6e, alquinilo substituido con 0-2 R6e, un residuo carbocíclico (CH2)r- C3-10 substituido con 0-5 R5e, un sistema heterocíclico(CH2)r de 5-10 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-2 R6e ; R6b, cada vez que se presenta, se selecciona de H, alquilo C1-6 substituido con 0-2 R6e, alquenilo C3-8 substituido con 0-2 R6e, alquinilo C3-8 substituido con 0-2 R6e, un residuo carbocíclico(CH2)r- C3-6 substituido con 0-3 R6e, un sistema heterocíclico(CH2)r de 5-6 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-2 R6e ; R6d cada vez que se presenta, se selecciona de alquenilo C3-8 substituido con 0-2 R6e, alquinilo C3-8 substituido con 0-2 R6e, metilo, CF3, alquilo C2-6 substituido con R6e, haloalquilo C2-4, un residuo carbocíclico(CH2)r- C3-10 substituido con 0-3 R6e, un sistema heterocíclico(CH2)r de 5-6 miembros que contiene 1-4 heteroátomos seleccionado de N, O, y S, substituido con 0-3 R6e; R6e, cada vez que se presenta, se selecciona de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo(CH2)r C3-6, Cl, F, Br, I, CN, NO2, (CF2)rCFu, alquilo(CH2)rO C1-6OH, SH, alquilo (CH2)rS C1-6, (CH2)rNR6fR6f, y (CH2)rfenilo; R6f, cada vez que se presenta, se selecciona de H, alquilo C1-5, y cicloalquilo C3-6, y fenilo; R6g se selecciona independientemente de -C(O)R6b, -C(O)OR6d, -C(O)NR6fR6f, y (CH2)rfenilo; R7, cada vez que se presenta, se selecciona de alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo(CH2)r C3-6, Cl, Br, I, F, NO2, CN, (CR'R')rNR7aR7a, (CR'R')rOH, (CR'R')rO(CR'R')rR7d, (CR'R')rSH, (CR'R')rC(O)H, (CR'R')rS(CR'R')rR7d, (CR'R')rC(O)OH, (CR'R')rC(O)(CR'R')rR7b, (CR'R')rC(O)NR7aR7a, (CR'R')rNR7fC(O)(CR'R')rR7b, (CR'R')rC(O)O(CR'R')rR7d, (CR'R')rOC(O)(CR'R') rR7b, (CR'R')rOC(O)NR7a(CR'R')rR7a, (CR'R')rNR7aC(O)NR7a(CR'R')rR7a, (CR'R')rNR7fC(O)O(CR'R')rR7d, (CR'R')rC(=NR7f)NR7aR7a, (CR'R')rNHC(=NR7f)NR7f
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44685003P | 2003-02-12 | 2003-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043694A1 true AR043694A1 (es) | 2005-08-10 |
Family
ID=32869560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040100419A AR043694A1 (es) | 2003-02-12 | 2004-02-11 | Derivados ciclicos como moduladores de la actividad del receptor de quimiocina |
Country Status (10)
Country | Link |
---|---|
US (3) | US7183270B2 (es) |
EP (2) | EP1606255B1 (es) |
AR (1) | AR043694A1 (es) |
AT (1) | ATE448200T1 (es) |
CL (1) | CL2004000255A1 (es) |
DE (1) | DE602004024045D1 (es) |
ES (2) | ES2387938T3 (es) |
PE (1) | PE20040951A1 (es) |
TW (1) | TW200508224A (es) |
WO (1) | WO2004071460A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005506949A (ja) | 2000-12-20 | 2005-03-10 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | ケモカイン受容体の調節剤としてのジアミン |
CA2432369A1 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Pharma Company | Cyclic derivatives as modulators of chemokine receptor activity |
ITRE20010042A1 (it) * | 2001-04-24 | 2002-10-24 | Corghi Spa | Dispositivo sollevatore per macchine smontagomme |
WO2003075853A2 (en) | 2002-03-08 | 2003-09-18 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US7338975B2 (en) | 2003-02-12 | 2008-03-04 | Bristol-Myers Squibb Co. | Lactams as modulators of chemokine receptor activity |
TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US7230133B2 (en) | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US7317019B2 (en) * | 2003-08-21 | 2008-01-08 | Bristol Myers Squibb Co. | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
EP1692506A4 (en) * | 2003-11-17 | 2008-01-09 | Janssen Pharmaceutica Nv | MODELING A SYSTEMIC INFLAMMATORY RESPONSE TO INFECTION |
US7541468B2 (en) * | 2004-06-10 | 2009-06-02 | Bristol-Myers Squibb Company | Process of preparing N-ureidoalkyl-piperidines |
EP1830841B1 (en) * | 2004-12-20 | 2008-07-02 | Eli Lilly And Company | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
JPWO2006104280A1 (ja) * | 2005-03-31 | 2008-09-11 | 武田薬品工業株式会社 | 糖尿病の予防・治療剤 |
US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US20100016289A1 (en) * | 2005-11-01 | 2010-01-21 | Kevin Sprott | Compounds Useful as Antagonists of CCR2 |
US8067415B2 (en) * | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
WO2007076034A2 (en) * | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
US7629351B2 (en) | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
US7687508B2 (en) | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
AU2007303846B2 (en) | 2006-10-04 | 2011-03-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists |
TWI399380B (zh) | 2006-12-20 | 2013-06-21 | Abbott Lab | 抗病毒化合物 |
US20090324596A1 (en) | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
AR074830A1 (es) | 2008-12-19 | 2011-02-16 | Cephalon Inc | Pirrolotriazinas como inhibidores de alk y jak2 |
JP2012513410A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
US8541424B2 (en) * | 2008-12-23 | 2013-09-24 | Abbott Laboratories | Anti-viral compounds |
RU2541571C2 (ru) * | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
SG171708A1 (en) | 2009-06-11 | 2011-07-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
WO2013019966A1 (en) | 2011-08-04 | 2013-02-07 | Allergan, Inc. | Aromatic bycyclic derivatives as cxcr4 receptor modulators |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
CN103910688B (zh) * | 2013-01-04 | 2016-05-25 | 陈春麟 | 2-丙基-4-氯喹唑啉衍生物及其制备方法和应用 |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
EP3409674B1 (en) | 2013-10-17 | 2022-04-06 | Blueprint Medicines Corporation | Process for preparing compositions useful for treating disorders related to kit |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
CN106831441B (zh) * | 2017-01-23 | 2019-04-02 | 江苏康思尔医药科技有限公司 | 一种盐酸西那卡塞的制备方法 |
WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
US10588894B2 (en) | 2017-06-21 | 2020-03-17 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
BR112020008833A2 (pt) * | 2017-11-02 | 2020-10-20 | Calico Life Sciences Llc | moduladores da via de estresse integrada |
EP3704115A1 (en) | 2017-11-02 | 2020-09-09 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
AU2019232704B2 (en) | 2018-03-05 | 2024-03-21 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
WO2020210293A1 (en) | 2019-04-12 | 2020-10-15 | Blueprint Medicines Corporation | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
DK3856341T3 (da) | 2019-04-12 | 2023-12-04 | Blueprint Medicines Corp | Krystallinske former af (s)-1-(4-fluorphenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amin og fremgangsmåder til fremstilling deraf |
KR20220158290A (ko) * | 2020-02-21 | 2022-11-30 | 미토키닌, 인크. | 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법 |
US20230357239A1 (en) | 2020-09-18 | 2023-11-09 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
BG113517A (bg) * | 2022-04-04 | 2023-10-16 | "Мицар Иновейшън" ООД | Пан-хемокинови антагонисти за използване при превенция и намаляване на ракови метастази |
WO2024056782A1 (en) | 2022-09-16 | 2024-03-21 | Bayer Aktiengesellschaft | Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer |
WO2024079252A1 (en) | 2022-10-13 | 2024-04-18 | Bayer Aktiengesellschaft | Sos1 inhibitors |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2653123B1 (fr) * | 1989-10-17 | 1992-01-17 | Roussel Uclaf | Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
US5892039A (en) | 1995-08-31 | 1999-04-06 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
DE19614204A1 (de) | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6011052A (en) * | 1996-04-30 | 2000-01-04 | Warner-Lambert Company | Pyrazolone derivatives as MCP-1 antagonists |
WO1997044329A1 (en) | 1996-05-20 | 1997-11-27 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
WO1998006703A1 (en) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
CN1279668A (zh) | 1997-11-18 | 2001-01-10 | 帝人株式会社 | 环胺衍生物及其作为药物的用途 |
UA59433C2 (uk) * | 1998-01-27 | 2003-09-15 | Авентіс Фармасьютікалс Продактс Інк. | ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ |
GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
US6541208B1 (en) | 1998-03-17 | 2003-04-01 | University Of Maryland Biotechnology Institute | Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia |
GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
WO2000069815A1 (en) | 1999-05-13 | 2000-11-23 | Teijin Limited | Ureido-substituted cyclic amine derivatives and their use as drug |
ATE277903T1 (de) | 1999-05-14 | 2004-10-15 | Bristol Myers Squibb Pharma Re | Zyklische aminderivate und ihre verwendung |
TWI263636B (en) | 1999-09-16 | 2006-10-11 | Ciba Sc Holding Ag | Fluorescent maleimides and use thereof |
US6957214B2 (en) | 2000-06-23 | 2005-10-18 | The Johns Hopkins University | Architecture for distributed database information access |
US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
US20040072860A1 (en) | 2000-09-29 | 2004-04-15 | Bing-Yan Zhu | Piperazin-2-one amides as inhibitors of factor xa |
CA2432369A1 (en) * | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Pharma Company | Cyclic derivatives as modulators of chemokine receptor activity |
JP2005506949A (ja) | 2000-12-20 | 2005-03-10 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | ケモカイン受容体の調節剤としてのジアミン |
EP1368354A1 (en) | 2001-03-07 | 2003-12-10 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
CA2341779A1 (en) | 2001-03-20 | 2002-09-20 | Marco Blouin | Inert electrode material in nanocrystalline powder form |
GB0114867D0 (en) | 2001-06-18 | 2001-08-08 | Merck Sharp & Dohme | Therapeutic agents |
WO2003043988A1 (fr) | 2001-11-22 | 2003-05-30 | Ono Pharmaceutical Co., Ltd. | Composes derives de piperidine-2-one et medicaments contenant lesdits composes comme principes actifs |
WO2003075853A2 (en) | 2002-03-08 | 2003-09-18 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
US7338975B2 (en) * | 2003-02-12 | 2008-03-04 | Bristol-Myers Squibb Co. | Lactams as modulators of chemokine receptor activity |
US7230133B2 (en) * | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
-
2004
- 2004-02-09 TW TW093102955A patent/TW200508224A/zh unknown
- 2004-02-11 EP EP04710294A patent/EP1606255B1/en not_active Expired - Lifetime
- 2004-02-11 US US10/776,828 patent/US7183270B2/en active Active
- 2004-02-11 DE DE602004024045T patent/DE602004024045D1/de not_active Expired - Lifetime
- 2004-02-11 WO PCT/US2004/004418 patent/WO2004071460A2/en active Application Filing
- 2004-02-11 ES ES09075272T patent/ES2387938T3/es not_active Expired - Lifetime
- 2004-02-11 ES ES04710294T patent/ES2334569T3/es not_active Expired - Lifetime
- 2004-02-11 AR ARP040100419A patent/AR043694A1/es not_active Application Discontinuation
- 2004-02-11 EP EP09075272A patent/EP2098508B1/en not_active Expired - Lifetime
- 2004-02-11 AT AT04710294T patent/ATE448200T1/de not_active IP Right Cessation
- 2004-02-12 CL CL200400255A patent/CL2004000255A1/es unknown
- 2004-02-12 PE PE2004000154A patent/PE20040951A1/es not_active Application Discontinuation
-
2006
- 2006-10-10 US US11/545,584 patent/US7338947B2/en not_active Expired - Lifetime
-
2008
- 2008-01-23 US US12/018,266 patent/US20080114052A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1606255A4 (en) | 2007-02-07 |
DE602004024045D1 (de) | 2009-12-24 |
CL2004000255A1 (es) | 2005-03-18 |
EP2098508B1 (en) | 2012-06-20 |
PE20040951A1 (es) | 2005-01-12 |
EP1606255A2 (en) | 2005-12-21 |
US20080114052A1 (en) | 2008-05-15 |
US20070032541A1 (en) | 2007-02-08 |
ES2387938T3 (es) | 2012-10-04 |
US7338947B2 (en) | 2008-03-04 |
ATE448200T1 (de) | 2009-11-15 |
TW200508224A (en) | 2005-03-01 |
EP1606255B1 (en) | 2009-11-11 |
ES2334569T3 (es) | 2010-03-12 |
WO2004071460A2 (en) | 2004-08-26 |
EP2098508A1 (en) | 2009-09-09 |
US7183270B2 (en) | 2007-02-27 |
US20040186140A1 (en) | 2004-09-23 |
WO2004071460A3 (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR043694A1 (es) | Derivados ciclicos como moduladores de la actividad del receptor de quimiocina | |
AR035773A1 (es) | Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina | |
AR035720A1 (es) | Derivados de amida ,composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de quimioquinas | |
AR073138A1 (es) | Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol | |
AR078944A1 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
AR034257A1 (es) | Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas | |
ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
AR058380A1 (es) | Inhibidores del factor viia macrociclicos utiles como anticoagulantes | |
PE20071176A1 (es) | Derivados diamina como inhibidores de leucotrieno a4 hidrolasa | |
AR086367A1 (es) | Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka | |
AR047085A1 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad | |
AR066273A1 (es) | Agentes anti- hipertensivos de accion dual | |
ES2640911T3 (es) | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus | |
AR049647A1 (es) | Cis-imidazolinas | |
RU2008142834A (ru) | Модуляция церамидкиназы | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR092838A1 (es) | COMPUESTOS TIPO PIRROLO-PIRROLIDINONA COMO INHIBIDORES DE LA INTERACCION ENTRE p53 Y MDM2 Y/O MDM4 | |
AR086977A1 (es) | Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen | |
AR066445A1 (es) | Inhibidores de la proteina activadora de la 5- lipoxigenasa (flap) | |
NI200800247A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
AR064010A1 (es) | Inhibidores de la actividad de la akt | |
AR057712A1 (es) | Dihidropteridinonas en el tratamiento de enfermedades respiratorias | |
AR064471A1 (es) | Macrociclos inhibidores selectivos del factor de coagulacion viia, composiciones farmaceuticas que los comprenden y uso de los mismos como agentes anticoagulantes. | |
AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
PE20080061A1 (es) | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |